The approval of CD19-directed chimeric antigen receptor (CAR) T-cell therapies for the
second-line treatment of high-risk large B-cell lymphoma (LBCL) has greatly affected …

ABSTRACT Introduction Chimeric Antigen Receptor;(CAR) T cells therapies have become
part of the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell …

Chimeric antigen receptor (CAR) T-cell therapy (CART) for central nervous system
lymphoma (CNSL) is a promising strategy, yet responses are frequently not durable …

Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening autoimmune
disorder caused by a disintegrin and metalloproteinase with thrombospondin type 1 motif …

Anti‐CD19 chimeric antigen receptor T‐cell therapy (CART) has revolutionized the
outcomes of relapsed and/or refractory B‐cell non‐Hodgkin lymphoma. However, CART is …

Large B-cell lymphomas (LBCLs) are among the most frequent (about 30%) non-Hodgkin's
lymphoma. Despite the aggressive behavior of these lymphomas, more than 60% of patients …

Chimeric antigen receptor T (CAR-T) cell therapy, a groundbreaking immunotherapy.
However, it faces formidable challenges in treating solid tumors, grappling with issues like …

Purpose: Greater disease burden is a well-established predictor of poorer outcomes
following chimeric antigen receptor T-cell (CAR T) therapy. Although bridging therapy (BT) is …

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of patients
with relapsed or refractory hematologic malignancies, but it comes with unique toxicities …

Radiation therapy (RT) for lymphomas has improved dramatically with modern imaging and
treatment techniques, encompassing only the necessary volume with minimal doses to …